Lessons from Gilead: Q&A with the CEO of one of the newest public biotechs

Kronos CEO Norbert Bischofberger, whose company raised more than $250 million in its IPO, talks about the flow of cash into the biotech industry, its "Zoom show" and survival of the fittest.